medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Número 12

<< Anterior Siguiente >>

Ginecol Obstet Mex 2021; 89 (12)


Anticoncepción en la paciente con enfermedad hepática, revisión bibliográfica

Vélez-Cuervo SM, Villegas-Ortiz, MÁ

Idioma: Español
Referencias bibliográficas: 35
Paginas: 963-970
Archivo PDF: 237.70 Kb.


RESUMEN

Objetivo: Describir recomendaciones anticonceptivas actualizadas para pacientes con enfermedad hepática, basadas en una revisión bibliográfica.
Metodología: Búsqueda bibliográfica en PubMed, LILACS y Google Scholar; entre los años 1960 a diciembre del 2020, con las palabras clave (Mesh): “Contraception”, “Liver Diseases”, “Hepatitis”, “Liver Cirrhosis”, “Cholelithiasis”, “Cholestasis”, “Liver Neoplasms”, “Adenoma”, “Focal Nodular Hyperplasia”, “Hepatolenticular Degeneration”, “Liver Transplantation”.
Resultados: Se obtuvieron 127 resultados, se excluyeron 92, por duplicidad, idioma diferente al inglés y español, no pertinencia para el tema y por no contar con texto disponible. Se incluyeron finalmente 35 artículos con información respecto de los efectos de los anticonceptivos hormonales y no hormonales en la aparición, evolución y tratamiento de las enfermedades hepáticas, que motivaron la revisión y análisis para poder establecer recomendaciones para la elección del mejor método anticonceptivo en mujeres con hepatopatías específicas.
Conclusiones: La asesoría anticonceptiva para las mujeres con enfermedad hepática es un reto que implica equilibrar el riesgo del método anticonceptivo en comparación con un embarazo de alto riesgo. Si bien las hormonas sexuales parecen tener un efecto negativo en algunas hepatopatías existen métodos de anticoncepción seguros y eficaces para mujeres con enfermedades hepáticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Toro LG, Calle LF, Ocampo A, Velez SM, et al. Enfermedades hepáticas y embarazo. Rev Colomb Gastroenterol 2019; 385-98. https://doi.org/10.22516/25007440.367

  2. Connolly TJ, Zuckerman AL. Contraception in the patient with liver disease. Semin Perinatol 1998; 70 (821): 162-84. https://doi.org/10.1016/s0146-0005(98)80050-5

  3. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981; 1 (2): 116-28. https://doi.org/10.1055/s-2008-1040724

  4. Mancinelli R, Onori P, DeMorrow S, et al. Role of sex hormones in the modulation of cholangiocyte function. World J Gastrointest Pathophysiol 2010; 1 (2): 50-62. https://doi. org/10.4291/wjgp.v1.i2.50

  5. De Benedetti VMG, Welsh JA, Yu MC, et al. P53 Mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 1996; 17 (1): 145-9. https://doi. org/10.1093/carcin/17.1.145

  6. Maheshwari S, Sarraj A, Kramer J, et al. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007; 47 (4): 506-13. https://doi.org/10.1016/j.jhep.2007.03.015

  7. World health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: Switzerland, 2015; 1-276 https://www.ncbi.nlm.nih.gov/books/NBK321151/

  8. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use. Recommendations and Reports 2016; 65 (3): 1-104. https://doi.org/10.15585/ mmwr.rr6503a1

  9. Charlton BM, Rich-Edwards JW, Colditz GA, et al. Oral contraceptive use and mortality after 36 years of followup in the Nurses’ Health Study: Prospective cohort study. BMJ 2014; 349: g6356. https://doi.org/10.1136/bmj.g6356

  10. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol 2017; 216 (6): 580.e1-580. e9. https://doi.org/10.1016/j.ajog.2017.02.002

  11. Acosta CR. Actualización Sobre Hepatitis Viral : Etiología , patogenia, diagnóstico microbiológico y prevención. Rev Cuba Med Gen Integr 2000; 16 (6): 574-85. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid =S0864-21252000000600009

  12. Shaaban MM, Hammad WA, Fathalla MF, Ali MY, et al. Effects of oral contraception on liver function tests and serum proteins in women with past viral hepatitis. Contraception 1982; 26 (1): 65-74. https://doi.org/10.1016/0010- 7824(82)90173-1

  13. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80 (4): 381-6. https://doi.org/10.1016/j.contraception. 2009.04.007

  14. Koo JS, Haeryoung K, Park BK, Ahn SH, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 2008; 42 (6): 738-43. https://doi.org/10.1097/ MCG.0b013e318038159d

  15. Sridhar A, Cwiak CA, Kaunitz AM, Allen RH. Contraceptive Considerations for Women with Gastrointestinal Disorders. Dig Dis Sci 2017; 62 (1): 54-63. https://doi.org/10.1007/ s10620-016-4383-z

  16. Lynn J. Ginsberg RL Garnick MB, Bennett PH.. Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med 1966; 274: 1473-6. https://doi.org/10.1056/ NEJM197601222940403

  17. Wang S, Wang Y, Xu J, Chen Y. Is the oral contraceptive or hormone replacement therapy a risk factor for cholelithiasis. Med (United States). 2017; 96 (14): 1-5. https://doi. org/10.1097/MD.0000000000006556

  18. Ponnatapura J, Kielar A, Burke LMB, Lockhart ME, et al. Hepatic complications of oral contraceptive pills and estrogen on MRI: Controversies and update - Adenoma and beyond. Magn Reson Imaging 2019; 60: 110-21. https:// doi.org/10.1016/j.mri.2019.04.010

  19. Anand V, Gorard DA. Norethisterone-induced cholestasis. QJM - Mon J Assoc Physicians 2005; 98 (3): 232. https:// doi.org/10.1093/qjmed/hci031

  20. Fernández E, Pérez E, González C, Ortiz MI, et al. Immunomodulatory effects by oral contraceptives in normal and cholestatic female rats: Role of cytokines. Int Immunopharmacol 2014; 21 (1): 10-9. https://doi.org/10.1016/j. intimp.2014.03.022

  21. Edmondson HA, Henderson BB, Benton B. Liver-cell adenomas associated with use of oral contraceptives. New Engl J Med 1976; 314 (3): 144-9. https://doi.org/10.1056/ nejm197602262940904

  22. Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991; 43 (6): 643-52. https://doi.org/10.1016/0010-7824(91)90007-3

  23. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 302 (7835): 926-9. https://doi.org/10.1016/ s0140-6736(73)92594-4

  24. Rooks JB, Ory HW, Ishak KG. Epidemiology of Hepatocellular Adenoma. JAMA 1979; 242 (7): 644. https://doi. org/10.1001/jama.1979.03300070040020

  25. Mathew RP, Manolea F, Girgis S, Patel V, et al. Malignant transformation of hepatic adenoma complicated by rupture and hemorrhage: An extremely rare clinical entity. Intractable Rare Dis Res 2019; 8 (4): 266-70. https://doi. org/10.5582/irdr.2019.01089

  26. Brady PC, Missmer SA, Laufer MR. Hepatic adenomas in adolescents and young women with endometriosis treated with norethindrone acetate. J Pediatr Adolesc Gynecol 2017; 30 (3): 422-4. https://doi.org/10.1016/j.jpag.2016.12.002

  27. Scalori A, Tavani A, Gallus S, La Vecchia C, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: A case-control study. Am J Obstet Gynecol 2002; 186 (2): 195-7. https://doi.org/10.1067/mob.2002.120277

  28. Vincent FD, Doll R. Cancer of the liver and the use of oral contraceptives. JAMA 1986; 256 (17): 2346. https://doi. org/10.1136/bmj.292.6532.1357

  29. Heinemann LAJ, DoMinh T, Guggenmoos I, Thie C, et al. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997; 56 (5): 275-84 https://doi.org/10.1016/S0010- 7824(97)00158-3

  30. Wang SN, Yeh YT, Yang SF, Chai CY, et al. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 2006; 59 (9): 930-4. https://doi.org/10.1136/ jcp.2005.033464

  31. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80 (4): 387-90. https://doi.org/10.1016/j. contraception.2009.01.021

  32. Haimov R, Ackerman Z, Anteby EY. The contraceptive choice for a Wilson’s disease patient with chronic liver disease. Contraception 1997; 56 (4): 241-4. https://doi. org/10.1016/s0010-7824(97)00141-8

  33. Riely CA. Contraception and pregnancy after liver transplantation. Liver Transplant 2001; 7 (11 Suppl 1): s74-6. https://doi.org/10.1053/jlts.2001.28644

  34. Zieniewicz Z, Bobrowska K, Kaminski P, Wielgos M, et al. Low-Dose Hormonal Contraception After Liver Transplantation. Transplant Proc 2007; 39 (5): 1530-2. https://doi. org/10.1016/j.transproceed.2007.02.063

  35. Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med 1981. https://pubmed.ncbi.nlm.nih.gov/7012338/




2020     |     www.medigraphic.com